Oruka Therapeutics (ORKA) EBIT (2010 - 2024)

Oruka Therapeutics' EBIT history runs 15 years deep, the most recent figure standing at -$3.1 million for Q2 2024.

• In Q2 2024, EBIT fell 58.24% year-over-year to -$3.1 million; the TTM figure through Jun 2024 stood at -$9.1 million (down 16.04% YoY), while the FY2023 annual figure was -$7.3 million, up 31.14% from the prior year.
• EBIT was -$3.1 million for Q2 2024 at Oruka Therapeutics, down from -$2.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.3 million in Q2 2020 to a low of -$5.7 million in Q4 2021.
• Historically, EBIT has averaged -$2.9 million across 5 years, with a median of -$2.5 million in 2022.
• The sharpest annual moves came in 2020 and 2022: EBIT slumped 301.1% in 2020, then soared 72.75% in 2022.
• A 5-year view of EBIT shows it stood at -$5.1 million in 2020, then slipped by 10.81% to -$5.7 million in 2021, then jumped by 72.75% to -$1.5 million in 2022, then dropped by 2.71% to -$1.6 million in 2023, then slumped by 96.35% to -$3.1 million in 2024.
• The last three EBIT figures came in at -$3.1 million (Q2 2024), -$2.5 million (Q1 2024), and -$1.6 million (Q4 2023), per Business Quant data.